MINTEZOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mintezol, and what generic alternatives are available?
Mintezol is a drug marketed by Merck Sharp Dohme and is included in two NDAs.
The generic ingredient in MINTEZOL is thiabendazole. There is one drug master file entry for this compound. Additional details are available on the thiabendazole profile page.
Summary for MINTEZOL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 144 |
Patent Applications: | 3,186 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MINTEZOL at DailyMed |
US Patents and Regulatory Information for MINTEZOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Sharp Dohme | MINTEZOL | thiabendazole | SUSPENSION;ORAL | 016097-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Merck Sharp Dohme | MINTEZOL | thiabendazole | TABLET, CHEWABLE;ORAL | 016096-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |